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THERE IS INCREASING EVIDENCE that
the cytoxic action of certain chemo-
therapeutic drugs may be enhanced more
in tumours than in normal tissues by
combining them with misonidazole
(MISO) (see reviews by Brown, 1982;
McNally, 1982). This is particularly true of
the alkylating agents and certain nitro-
soureas. For instance, Martin et al., (1981)
reported a dose-modifying factor (DMF) of
2 when 1 mg/g MISO was combined with
cyclophosphamide (Cy) against the
WHFIB tumour, with no effect of MISO
on the leucopenia induced by Cy. A similar
result was obtained with melphalan.
In contrast, the radioprotective drug
WR2721 has been reported to protect
certain normal tissues to a greater extent
than tumours from the cytotoxic action of
Cy (Yuhas etal., 1980; Twentyman, 1981),
nitrogen mustard (Yuhas, 1979), cis-
platinum (Yuhas & Culo, 1980), and a
range of cytoxic drugs including Cy,
nitrogen mustard and cis-platinum
(Wasserman et al., 1981).
I have therefore combined MISO and
WR2721 with either Cy or melphalan in an
attempt to increase the effectiveness ofthe
chemotherapeutic drugs in tumours due to
MISO potentiation, while reducing their
effects in normal tissues due to WR2721
protection, thus increasing the therapeutic
ratio. The normal tissue endpoint was
white cell depression.
The tumour used was the WHFIB
tumour growing in inbred WHT/GyfBSVS
mice. This is a poorly differentiated
sarcoma derivedfrom afibrosarcoma which
arose spontaneously in a WVHT mouse. It
has been adapted for growth in vitro so
that after treatment in vivo the response
can be assessed in terms of tumour cell
survival in vitro (George et al., 1977). The
methods used to obtain tumours and to
assay cell survival after treatment have
been described before (Martin et al., 1981).
Tumours were treated when they had
reached a mean diameter of 6-8 mm, when
the volume doubling time was about 3-5
days. The drugs were administered i.p. as a
solution in normal saline, except for
WR2721 which was dissolved in distilled
water. They were dissolved immediately
before use at a concentration such that the
volume injected would be either 0-01 or
0-02 ml/g body wt.
Leucopenia induced by Cy or melphalan
was assessed by drawing up a small
volume ofblood from the cut tip ofthe tail
of a mouse lightly anaesthetized with
penthrane into a heparinized capillary
tube. The blood was then diluted in 0.2%
acetic acid to lyse the red cells and the
white cells were counted using a haemo-
cytometer and phase contrast microscopy.
At least 5 mice were used for each dose
point.
It was shown previously that the cells of
the WHFIB tumour are capable of
recovering from the potentially lethal
damage induced by Cy or melphalan
(Martin et al., 1981). ConsequentlyTUMOUR RESPONSE TO MISO AND WR2721
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FiG. 1.-The effect of Cy (MISO 500 mg/kg; 2721 400 mg/kg) (A) or melphalan (MISO 800 mg/kg;
2721 300 mg/kg) (B) on tumour cell survival of the WHFIB tumour. Symbols: A, chemothera-
peutic drug alone; x, drug+WR2721; 0, drug+MISO; 0, drug+MISO+WR2721.
tumours were not excised until 24 h after
the drug was given in order to assess its
effect on cell survival. MISO has its
greatest effect on Cy or melphalan toxicity
when given 1 h before the drug (Martin et
al., 1981). WR2721 has its greatest
radioprotective effect when given about 40
min before radiation (Stewart & Rojas,
1982; Travis et al., 1982). The injection
schedule was therefore:
MISO-20 min-WR2721-40 min-Cy
or melphalan
Fig. 1 shows the effect of Cy or
melphalan on survival of the cells of the
WHFIB tumour treated in vivo and
assayed in vitro. The drugs were given
either alone or in combination with MISO
or WR2721, or MISO plus WR2721. The
additive toxicities of MISO and WR2721
limits the amount of the 2 drugs that can
be used together (Rojas et al., 1982).
Consequently the doses of the 2 were
adjusted to ensure that there should be
adequate potentiation of drug action by
MISO and yet enough WR2721, on the
basis of published results, to give chemo-
protection if there is any. The doses of
MISO and WR2721 were 500 and 400
mg/kg respectively with Cy and 800 and
300 mg/kg respectively with melphalan.
The doses differed because whereas 500
mg/kg MISO potentiates the action of Cy
upon the WHFIB tumour, a larger dose is
needed with melphalan (McNally, un-
published data). MISO enhanced the
action of Cy against the WHFIB tumour,
giving a DMF of about 2 (Fig. 1(A)).
WR2721 had no effect on Cytoxicity or its
potentiation by MISO. With melphalan,
MISO gave a DMF of about 2-4. Again
there was no effect ofWR2721 either with
or without MISO.
The data points in Fig. 1 represent
survival values for individual tumours
(not all treated on the same day). No
correction has been made for variations in
cell yield because no systematic effect of
the treatment on cell yield could be
detected. MISO and WR2721 either alone
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FiG. 2.- The effect ofCy either alone or with MISO or WR2721, or with both of them on leucopenia in
WHT mice. (A). The time course of leucopenia (Cy 100 mg/kg; MISO 500 mg/kg; 2721 400 mg/kg).
(B). Dose-effect relationship at Day 3 (MISO 500 mg/kg; 2721 400 mg/kg). Symbols: A,
controlmice (A); A,Cyalone; C,Cy+MISO; x, Cy+WR2721; *, Cy+AMISO and WVR2721. In
(B) the Cy doses were 75, 100, 150 and 225 mg/kg. The data points have been "clustered" aroundl
these dose values for clarity. Error bars represent 2 standard deviations from the mean as (lescribed
in the text.
or in combination, at the doses used, had
no effect on tumour cell survival.
The effect of Cy on the total white cell
count in mice without tumours is shown in
Fig. 2. Fig. 2(A) shows that the nadir in
the white cell count was reached 3 days
after injection ofthe Cy, with full recovery
following a dose of 100 mg/kg by Day 7.
Each data point in Fig. 2(A) represents the
average white cell count for 5 mice.
Previous studies have shown no effect of
MISO on the extent of or the time course
of the fall and subsequent recovery of the
white cell count due to Cy (McNally et al.,
1982). Neither MISO or WR2721 alone,
nor the two together, had any effect on the
nadir following 100 mg/kg Cy or on the
subsequent recovery in the white cell
count (Fig 2(A)). MISO and WR2721,
either alone or in combination, also had no
effect on control mice or the dose-effect
curve for depression in white cell count at
3 days induced by Cy (Fig. 2(B)). The
points in Fig. 2(B) represent the pooled
results from 3 experiments each using 5
mice per point for Cy alone or with MISO,
or 2 experiments when WR2721 was used.
The error bars represent 2 standard
deviations derived from the average white
cell count for all mice pooled together.
Neither MISO nor WR2721 either alone or
combined had any effect on the white cell
count of control mice.
Fig. 3 shows the effect of melphalan,
either alone or with MISO or WR2721, or
with both, on white cell depression assayed
5 days after injection. This had previously
been found to be the time of the nadir in
white cell count due to melphalan in this
strain of mice (McNally et al., 1982). The
points and error bars were obtained as de-
scribed for Fig. 2(B). As with Cy, MISO or
WR2721 separately had no effect on the
white cell depression due to melphalan.
The combination of 800 mg/kg MISO
and 300 mg/kg WR2721 was moderately
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MISO and Cy or melphalan. The WR2721
protected neither the tumour nor the
\ normal tissue from the toxic action of the
N \ chemotherapeutic drugs and had no effect
T TX on the potentiation of their toxicity by
rA~l MISO in the tumour.
Yuhas (1980) and Yuhas et al. (1980)
\TT found no effect of 200 mg/kg WR2721 on
. TAT - the growth delay induced by Cy in the
_ T O ~~X | mammary carcinoma Mca-1l, whereas it
N L x did protect the mice against the lethal
effects of Cy increasing the LD50/30 from _T!b OL 372 to 540 mg/kg. Twentyman (1981)
found a minimal effect of400 mg/kg on the
LD30/5o dose of Cy in mice although there
LT was significant protection at 200 mg/kg.
* He also found minimal protection by 400
mg/kg on the leucopenia induced by 33 or
100 mg/kg Cy although there was some
protection at 67 mg/kg. He also found
, s I 2 I some protection by WR2721 against the
0 4 8 12 action of Cy upon the RIF-1 and KHT tumours (Twentyman, 1981). The overall
MetphqtQn I mg/Kg conclusion was that there was minimal
The effect ofmelphalan either alone therapeutic gain from the use of WR2721
ith MISO or WR2721, or with both of with Cy. In contast, Wasserman et al.
1 on leucopenia in WHT mice (Day 1 1ISO 800 mg/kg; 2721 300 mg/kg). (1981) measured a small protective effect
bols and error bars as for Fig. 2(B). of 600 mg/kg on the effect of Cy in EMT6
data points have been "clustered" tumours, but a larger protective effect on
nd the melphalan dose values of 4,8 t
12 mg/kg. the bone marrow cells, leading to a
significant therapeutic gain.
the mice. In the first experiment The present results suggest that there is
h the 2 were used together no mice no differential protection against Cy or
though they all looked sick for the melphalan by WR2721 when comparing
lays. In the repeat experiment 6/20 effects on the WHFIB tumour and
ed between Days 1 and 3. The dose leucopenia in WHT mice. Also WR2721
halan they received did not seem to did not affect the potentiation of the
ortant although the numbers are action ofthese drugs by MISO against the
i1l for certainty. Death may have WHFIB tumour. There is evidence that at
lfrom the additive toxicitiesofthe a lower dose (200 mg/kg) WR2721 may
and WR2721 (Grigsby & Maru- show a greater protective effect in normal
1981), although it has been tissues (Twentyman, 1981), although in
ed that WR2721 enhances MISO the present study it had no protective
(Rojas et al., 1982). The increased effect at doses at 300 and 400 mg/kg.
toxicity was reflected in a reduced white
cell count for control mice treated with
MISO and WR2721 (Fig. 3). This accounts
for the increased effect of melphalan in
combination with MISO and WR2721.
Thus in this system there was no benefit
from the combination of WR2721l with
I thank Ms J. de Ronde and MIs M. Hinchcliffe for
expert technical assistance and the Cancer Research
Campaign for financial support. Roche Products,
Welwyn Garden City, kindly provided the misoni-
dazole and the WR2721 was provided by the
Development Programme, Division of Cancer Treat-
ment, NCI, Bethesda, U.S.A.
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